Akari Therapeutics, Plc (ADR)

General ticker "AKTX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $5.2K (TTM average)

Akari Therapeutics, Plc (ADR) does not follow the US Stock Market performance with the rate: -30.9%.

Estimated limits based on current volatility of 16.2%: low 0.31$, high 0.43$

Factors to consider:

  • Total employees count: 12 as of 2023
  • Top business risk factors: Going concern, Operating losses, Labor/talent shortage/retention, Climate change and natural disasters, Supply chain disruptions
  • Current price 69.0% below estimated low
  • Earnings for 18 months up through Q2 (+1 year) are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.68$, 5.67$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.10$, 3.91$]

Financial Metrics affecting the AKTX estimates:

  • Positive: with PPE of 1.5 at the end of fiscal year the price was very low
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -111506.00 <= 0.33
  • Negative: negative Industry operating cash flow (median)
  • Negative: Shareholder equity ratio, % of -5.26 <= 18.93
  • Negative: negative Net income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Investing cash flow per share per price, % of 0 > -0.66

Similar symbols

Short-term AKTX quotes

Long-term AKTX plot with estimates

Financial data

YTD 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM
Operating Expenses $23.09MM $16.81MM
Operating Income $-23.09MM $-16.81MM
Non-Operating Income $5.34MM $6.80MM
R&D Expense $9.56MM $5.45MM
Income(Loss) $-17.75MM $-10.01MM
Profit(Loss)* $-17.75MM $-10.01MM
Stockholders Equity $1.79MM $-0.23MM
Assets $13.83MM $4.36MM
Operating Cash Flow $-21.50MM $-16.43MM
Financing Cash Flow $25.29MM $7.02MM
Earnings Per Share** $-5,686.64 $-2,044.95
Ordinary share to ADR 0.00x 0.00x

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.